Replies to post #10 on Satellos Bioscience Inc (MSCLF)

[makingmoneynow]

I think iCo Therapeutics will see a busy 2014 ahead, with both primary end data and HIV results coming in the first Half of next year.

Not too many followers in the US suggests that whilst the stock is currently undervalued, once discovered, those in already will get even better rewarded.

Q1 should see a nice run towards primary efficacy data from Phase 2.

Good luck to all of you in,

MMN